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Abstract
Regulation of mesenchymal stem cell (MSC) lineage selection is important for the generation of
bone mass. Inhibition of cyclooxygenase-2 (COX2) may increase adipogenesis at the cost of
decreasing osteoprogenitor output. Here we investigated the role of COX2 and its products during
MSC differentiation. Indomethacin stimulated adipogenesis (increased aP2, adiponectin and lipid
droplets) of CH310T1/2 stem cells as well as marrow-derived MSCs to a degree similar to the
PPARγ2 ligand, rosiglitazone. Unlike rosiglitazone, indomethacin significantly upregulated
PPARγ2 expression. Indomethacin and the COX2 specific inhibitor celecoxib suppressed PGE2
production, but celecoxib did not induce adipogenesis. As well, addition of PGE2 failed to reverse
indomethacin induced adipogenesis, indicating that indomethacin’s effects were prostaglandin
independent. In MSCs over-expressing PPARγ2 and RXRα, indomethacin did not increase
PPAR-induced transcription, while rosiglitazone and 15d-PGJ2 did (1.7- and 1.3-fold,
respectively, P < 0.001). We considered whether indomethacin might directly affect C/EBPβ
proximally to PPARγ2 induction. Indomethacin significantly increased C/EBPβ expression and
protein within 24 h of addition. These results indicate that indomethacin promotes adipogenesis by
increasing C/EBPβ and PPARγ2 expression in a prostaglandin-independent fashion. This effect of
indomethacin is pertinent to potential deleterious effects of this commonly used anti-inflammatory
drug on bone remodeling and tissue healing.
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As the progenitor of bone forming cells, the mesenchymal stem cell (MSC) is critical to
bone modeling, remodeling and fracture healing. Importantly, a reciprocal relationship exists
between the number of adipocytes and osteoblasts generated from the marrow MSC pool
[Akune et al., 2004; Sen et al., 2008]. As such, factors which enhance adipogenic
differentiation may negatively impact bone remodeling. Frequently used as analgesics
during processes of tissue repair, non-steroidal anti-inflammatory drugs (NSAIDs), and in
particular the non-specific cyclooxygenase (COX) inhibitor indomethacin, have been shown
to promote adipogenesis and decrease osteogenesis. In vitro culture systems frequently use
indomethacin to enhance pre-adipocyte differentiation into mature adipocytes [Williams and
Polakis, 1977; Verrando et al., 1981; Knight et al., 1987; Kelly and Gimble, 1998] and it has
also been shown to be pro-adipocytic at an earlier stage [Lehmann et al., 1997; Dennis et al.,
1999]. The mechanism for the pro-adipogenic effect of indomethacin is controversial. It has
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been suggested that inhibition of prostaglandin production might underwrite effects on
lineage [Zhang et al., 2002]. Alternatively, indomethacin as well as other NSAIDs may
serve as ligands for PPARγ, enhancing transcription of critical gene targets important for fat
formation [Lehmann et al., 1997].
The rate-limiting step in the conversion of arachidonic acid to prostaglandins is catalyzed by
cyclooxygenases, which are inhibited by commonly used NSAIDs. Cyclooxygenase-2
(COX2) and its principal product prostaglandin E2 (PGE2) are thought to play a positive
role in bone formation [Cheng et al., 1997; Yoshida et al., 2002; Zhang et al., 2002; Arikawa
et al., 2004; Choudhary et al., 2008]. As such, COX2-selective NSAIDs have been
associated with delayed fracture healing in rabbits, mice and rats [Goodman et al., 2002;
Simon et al., 2002; Naik et al., 2009]; further, they have been shown to decrease the
anabolic response to physical loading in rats [Chow and Chambers, 1994; Forwood, 1996].
As well, microCT analysis demonstrates decreased bone density in COX2−/− male mice
[Robertson et al., 2006] and marrow cultures from these mice suggest that osteoclast
formation is impaired [Okada et al., 2000]. Importantly, COX2−/− mice display delayed
fracture healing and bone marrow stromal cells harvested from these animals form bone
nodules at a delayed rate [Zhang et al., 2002]. With respect to bone modeling, administration
of PGE2 to animals has been associated with reduced longitudinal growth of bones but an
increase in trabecular bone area [Ueno et al., 1985; Suponitzky and Weinreb, 1998]. Taken
together, this data suggests that the complex effect of NSAIDs on bone can be only partially
explained by the inhibition of cyclooxygenases and reduced prostanoid generation.
Developing concepts in the understanding of bone formation indicate that factors which
increase adipogenic differentiation of MSCs should have a reciprocal negative effect on
osteogenesis [Kang et al., 2007; Sen et al., 2008]. As such, NSAID effects on MSC lineage
selection that lead to adipocyte lineage differentiation should be important to processes that
require recruitment of alternate lineages.
In this study, we investigate the mechanism by which NSAIDs modulate adipogenesis in
C3H10T1/2 pluripotent stem cells as well as marrow-derived mesenchymal stem cells
(mdMSCs) [Case et al., 2010]. Our results show that PGE2 has only a minimal effect on
early MSC lineage allocation. In contrast, indomethacin promotes adipogenesis in a
prostaglandin-independent manner. We provide evidence that indomethacin’s adipogenic
influence is proximal to PPARγ induction. Our work suggests that indomethacin may have




Lipofectamine 2000, reverse transcriptase, siRNA and Taq polymerase were obtained from
Invitrogen (Carlsbad, CA). Arachidonic acid, PGE2, and 15-deoxy-PGJ2 were from Sigma–
Aldrich (St. Louis, MO). Rosiglitazone was obtained from Cayman Chemicals (Ann Arbor,
MI). Celecoxib was obtained from LKT Labs (St. Paul, MN). Luciferase assay reagents
were from Promega (Madison, WI).
CELL CULTURE
C3H10T1/2 pluripotent stem cells were maintained in growth medium (α-MEM, 10% FBS,
100 µg/ml penicillin/streptomycin). Cells were plated in six-well plates at a density of 1
i×105 except as otherwise noted one day prior to initiation of experiments. Adipogenic
medium including 0.1 µM dexamethasone and 5 µg/ml insulin was added on day zero. For
the 7-day experiments, adipogenic medium was replaced on day 4.
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Key experiments were replicated in a marrow derived mesenchymal stem cell line generated
from C56/BL6 wild-type mice using the procedure of Peister et al. [2004] and Case et al.
[2010]. These cells readily undergo differentiation into osteogenic, adipogenic or alternative
lineages using standard differentiation media [Case et al., 2010]. Cells were plated under
similar adipogenic conditions as detailed above. We have termed these cells “marrow
derived MSC” (mdMSC) in the text. Both C3H10T1/2 as well as mdMSC are referred to as
MSCs throughout the text; figure legends specify the cell type used.
RNA INTERFERENCE
Cells were transfected with siRNA (50 nm) in serum-free OptiMEM for 4–6 h using
lipofectamine 2000 reagent per the manufacturer protocol. After transfection, cells were
placed in adipogenic media. Three days after transfection, RNA and protein analyses were
performed.
PROTEIN ANALYSIS
Whole cell lysates were prepared with lysis buffer (150mM NaCl, 50mM Tris HCl, 1mM
EGTA, 0.24% sodium deoxycholate, 1%IGEPAL, pH 7.5) containing 25mM NaF and 2mM
Na3VO4, aprotinin, leupeptin, pepstatin and PMSF. Whole lysate proteins (15–20 µg) were
loaded onto a 8.5–12% polyacrylamide gel for chromatography and transferred to PVDF
membrane. After blocking, primary antibody was applied overnight at 4°C including
antibodies against active β-catenin (clone 8E7, Upstate, Temecula, CA), total β-catenin
(BD, Bedford, MA), PPARγ, adiponectin, COX2, β-tubulin (Santa Cruz, CA), aP2 (ProSci,
Inc., Poway, CA), and C/EBPβ (Cell Signaling, Danvers, MA). Secondary antibody
conjugated with horseradish peroxidase was detected with ECL plus chemiluminescence kit
(Amersham Biosciences, Piscataway, NJ). Densitometry was determined using NIH ImageJ,
1.37v.
REAL-TIME RT-PCR
Total RNA was isolated with the RNeasy mini kit (Qiagen, Valencia CA) and treated with
DNase I. Reverse transcription of 1 mg of RNA was performed prior to real-time PCR
(BioRad iCycler, Hercules, CA). Amplification reactions contained primers (0.5 µM),
dNTPs (0.2mM each), 0.03 U Taq polymerase and SYBR-green (Molecular Probes, Eugene,
OR) at 1:150,000. Aliquots of cDNA were diluted 5- to 5,000-fold to generate relative
standard curves to which sample cDNA was compared. PPARγ, adiponectin, COX2, and
18S primers were as in Case et al. [2008] and Sen et al. [2008]. For C/EBPβ forward and
reverse primers were 5′-CAAGCTGAG-CGACGAGTACA-3′ and 5′-
AGCTGCTCCACCTTCTTCTG-3′, respectively. Standards and samples were run in
triplicate. PCR products were normalized to 18S amplicons in the RT sample, and
standardized on a dilution curve from RT sample.
PLASMIDS, DNA TRANSFECTION, AND LUCIFERASE ASSAY
The FLAG-PPARγ2 plasmid was a gift from Dr. Monte Willis (UNC). The pCMV-RXRα
plasmid was a gift from Dr. Mark Nanes (Emory University) [Farmer et al., 2000]. Cells (1
× 105) were seeded in 12-well plates in duplicate. On day zero, cells were transfected with
FLAG-PPARγ2 (0.2 µg) and pCMV-RXRα (0.2 µg) versus pCDNA3.1 expression vector
(0.4 µg) as well as with the PPRE-luciferase construct pCPE −2.6 kb (29) (0.35 µg) versus
salmon sperm DNA (0.35 µg). β-Galactosidase (0.05 µg) was used to control for transfection
efficiency in all wells. Lipofectamine 2000 reagent was used according to the manufacturer
protocol (2 µl/well). Four to six hours after transfection, the media was changed to α-MEM.
Indomethacin, rosiglitazone, 15-deoxy-PGJ2 or vehicle was added 24 h after transfection.
Cell lysates were collected 48 h after transfection using the reporter lysis buffer (Promega).
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Luciferase assays were performed with the Luciferase Assay system (Promega) and Galacto-
Star™ (Applied Biosystems, Bedford, MA). Ninety six-well plates were read via the
GloMax Luminometer (Promega).
PGE2 ELISA MEASUREMENT
Cells (1×105) were seeded in 24-well plates in duplicate. One day later, cells were treated
with arachidonic acid, indomethacin and celecoxib at indicated concentrations. Twenty-four
hours later, cell culture media was analyzed PGE2 and ELISA kit from Assay Designs (Ann
Arbor, MI).
STATISTICAL ANALYSIS
Results are expressed as mean ± SEM. Statistical significance was evaluated by one-way
ANOVA with a Tukey’s post hoc test, a two-way ANOVA with a Bonferroni posttest or t-
test (GraphPad Prism). All experiments were replicated at least once to assure
reproducibility. Statistical significance is indicated on graphs as follows: *P < 0.05, **P <
0.01, ***P < 0.001.
RESULTS
INDOMETHACIN IS A POTENT STIMULATOR OF ADIPOGENESIS IN MSCs
MSCs were cultured in adipogenic media containing insulin and dexamethasone with
additions as noted of rosiglitazone, a known PPARγ ligand, indomethacin, or the specific
COX2 inhibitor, celecoxib. The cells were stained for oil red O stain to show presence of
lipid droplets indicating the formation of adipocytes. After 3 days in adipogenicmedia,
MSCs contained no lipid droplets (Fig. 1A). The addition of indomethacin (10 µM) induced
appearance of lipid droplets at a level similar to that of an equimolar dose of rosiglitazone.
The more commonly used adipogenic dose of indomethacin, 50 µM [Sen et al., 2008], or a
higher dose of rosiglitazone (20 µM) were able to further increase the number of lipid
containing cells by oil red O (data not shown). In contrast to indomethacin, celecoxib at
doses from 1 to 50 µM failed to induce adipogenesis. Celecoxib doses equal to or greater
than 20 µM were toxic to the MSCs with excessive cell death consistent with other reports
for other cells [Chuang et al., 2008].
Proteins consistent with adipogenic differentiation were analyzed. As shown in Figure 1B,
aP2 protein was equally upregulated by indomethacin and rosiglitazone at 50 and 10 µM
respectively, suggesting similar induction of adipogenesis. In contrast, PPARγ2 was more
significantly increased by indomethacin as compared with rosiglitazone by Western blot
(Fig. 1B). Densitometry of bands from at least two separate experiments show that while
doses of indomethacin, that had an equivalent effect to rosiglitazone to increase aP2, caused
a significantly greater increase in PPARγ2. Celecoxib failed to stimulate either PPARγ2 or
aP2 (1B).
We confirmed that indomethacin upregulates PPARγ2 and aP2 in marrow derived MSC.
Shown in Figure 1C, mdMSC treated with indomethacin 50 µM express both PPARγ2 or
aP2 protein, as well as stain for lipid (data not shown). Celecoxib did not cause adipogenesis
in mdMSCs (1C).
INDOMETHACIN ACCELERATES ADIPOGENESIS AND DECREASES β-CATENIN
Indomethacin induction of PPARγ2 mRNA was measurable by day 2 (Fig. 2A) resulting in
peak PPARγ protein at day 4 followed by a decline by day 7 (Fig. 2B). Adiponectin and aP2
proteins were also measurable by day 2, peaking at day 4 (Fig. 2B). The decrease in total
and active β-catenin that typically accompanies adipogenesis [Moldes et al., 2003; Sen et al.,
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2008, 2009] was accelerated in the presence of indomethacin (Fig. 2B). Similarly, COX2
expression was significantly reduced early in the course of adipogenesis as shown by RT-
PCR (Fig. 2A) and Western (Fig. 2B).
INDOMETHACIN’S ADIPOGENIC EFFECT IS INDEPENDENT OF COX2 AND PGE2
Indomethacin effectively induced adipogenesis at a dose of 5 µM, increasing both
adiponectin and aP2 protein at 2 days; celecoxib (5 µM) failed to replicate this effect (Fig.
3A, upper panel). Furthermore, indomethacin’s effect was dose dependent as evidenced by
increasing levels of aP2 protein expression with increases of the drug to 50 µM (Fig. 3A,
lower panel). Celecoxib increased aP2 above control levels at day 2 but this effect was not
dose dependent, and was not associated with increased adiponectin. This effect of celecoxib
on aP2 at the early time point was inconsistent and did not develop in the next several days.
This allowed us to conclude that this agent, which potently suppressed PGE2 production, did
not induce adipogenesis.
The effect of indomethacin to enhance adipogenesis has been attributed to the inhibition of
prostaglandins including the major product of the COX2 enzyme, PGE2. To confirm that
indomethacin and celecoxib successfully inhibited COX2, arachidonic acid was used to
stimulate PGE2 production by providing substrate for COX. PGE2 ELISA analysis of media
collected 24 h after treatments revealed robust PGE2 production in the presence of
arachidonic acid (Fig. 3B). Both indomethacin and celecoxib effectively prevented PGE2
production.
Furthermore, PGE2 addition did not inhibit adipogenesis. MSCs were cultured in adipogenic
media in the presence and absence of indomethacin along with PGE2 (5 µM) which was re-
added on day 2. Measured on day 4, indomethacin induction of expression of adiponectin
and PPARγ was unaffected by PGE2 addition (Fig. 4A). This was confirmed by Western
analysis (Fig. 4B).
To rule out a role for other COX2 generated prostaglandins, siRNA to COX2 was employed.
Seventy-two hours after transfection, siRNA knockdown of COX2 not only did not enhance
adipogenesis but appeared to have inhibitory effects on PPARγ2 and adiponectin expression
(Fig. 4C). Western blot data for adiponectin, aP2 and PPARγ2 supported this expression
data (Fig. 4D). COX2 knockdown was effective in cultures in growth media (data not
shown), but knockdown could not be demonstrated by Western blot as COX2 protein
decreased sharply during adipogenesis in all cultures.
INDOMETHACIN DOES NOT FUNCTION AS A PPARγ LIGAND IN MSC
Indomethacin has previously been shown to ligate PPARγ in C3H10T1/2 cells [Lehmann et
al., 1997]; thus we considered whether this could also serve as the mechanism by which
indomethacin affected aP2 and adiponectin expression. To control for indomethacin induced
changes in PPARγ level (see Fig. 1), both PPARγ2-FLAG and RXRα were transiently
overexpressed in MSCs prior to initiation of experiment. PPARγ2 expression was
confirmed by Western blot using antibodies to FLAG and PPARγ2 24 h after transfection
with the FLAG-PPARγ2 plasmid (Fig. 5A). PPARγ agonists rosiglitazone and 15d-PGJ2
significantly induced PPRE (1.7- and 1.3-fold that of control respectively, P < 0.01, Fig.
5B). In contrast, indomethacin increased PPRE-driven-luciferase (PPRE-LUC) activity to
1.1-fold that of control, an effect which was not significant. Additionally, indomethacin at
doses from 10 to 200 µM failed to activate PPRE-LUC (data not shown). Thus, at levels
which potently induced adipogenesis, indomethacin did not significantly enhance PPARγ
activated transcription.
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INDOMETHACIN INCREASES LEVELS OF C/EBPβ IN A DOSE-DEPENDENT ASHION
Given that indomethacin increases PPARγ2 expression and that C/EBPβ functions upstream
of PPARγ2, we investigated C/EBPβ as a possible target of indomethacin. C/EBPβ
expression increased in the presence of indomethacin in a time course that predicted the rise
in PPARγ2 and APN expression. C/EBPβ mRNA rose by day 2 and remained elevated at
day 3 (Fig. 6A, left panel) in the C3H10T1/2 stem cells. In mdMSCs C/EBPβ was similarly
induced by indomethacin at day 3 (Fig. 6A, right panel): expression of C/EBPβ was
increased fourfold by day 1 in adipogenic media without indomethacin and by day 3,
indomethacin maximally upregulated the expression of C/EBPβ to eightfold in three
separate experiments. Expression was confirmed by Western blot analysis showing that
upregulation of C/EBPβ protein occurred in a dose-dependent fashion (Fig. 6B). By day 3,
indomethacin’s effect on C/EBPβ protein expression was maximal.
DISCUSSION
Control of mesenchymal stem cell lineage selection is central to regeneration and repair of
tissues. In particular, the allocation of MSC into the adipogenic lineage at the expense of the
osteogenic output appears to contribute to bone pathology: increased marrow fat in place of
trabecular bone is associated with aging [Yeung et al., 2005], the nutritional defect in
anorexia nervosa [Abella et al., 2002] and with thiozolidinedione induced bone fragility
[Kahn et al., 2006; Grey, 2008]. The widely available non-steroidal anti-inflammatory class
of drugs (NSAIDs), have been shown to affect bone healing [Simon et al., 2002; Zhang et
al., 2002], an effect which has been presumed to be due to a primary role for the COX2
product, PGE2, on both osteogenesis and chondrogenesis [Zhang et al., 2002]. Human
studies provide inconclusive data in this regard but suggest NSAID may negatively affect
fracture healing [Adolphson et al., 1993; Burd et al., 2003]. Here we have shown that the
commonly used NSAID, indomethacin, has a unique and profound prostaglandin-
independent effect to promote adipogenesis in C3H10T1/2 pluripotent stem cells as well as
marrow-derived MSCs. As such, our work has implications for the use of this drug during
tissue repair, as it may limit the ability for MSCs to enter cell lineages critical to healing of
tissues. Prior work indicates that the C3H10T1/2 cell line is a faithful model of MSC stem
cell commitment in vitro [Tang et al., 2004; Bowers et al., 2006; Huang et al., 2009].
Additionally, when implanted into athymic mice, C3H10T1/2 stem cells treated with
adipogenic stimuli differentiate into tissue that is indistinguishable from endogenous adipose
tissue in vivo [Tang et al., 2004]. In order to confirm physiologic relevance of our findings
in the C3H10T1/2 stem cells, key experiments were reproduced using murine marrow-
derived MSCs as well; these experiments confirmed indomethacin’s effects to cause
adipogenesis.
The pro-adipogenic properties of indomethacin were recognized as early as the 1970s
[Williams and Polakis, 1977; Verrando et al., 1981; Knight et al., 1987] and the drug
became an established component of an adipogenic cocktail utilized in laboratories. The
mechanism of adipogenesis had been thought to involve either inhibition of PGE2 or by
enhancing the action of the central adipocyte transcription factor PPARγ. Our data indicates
that indomethacin’s unique role in promoting early adipogenesis is, in fact, separate from its
effects on COX2 or prostaglandins generated from COX2. Further, rather than enhancing
PPARγ-activated transcriptional activity, we found that indomethacin increased PPARγ2
protein to levels far above those seen after treatment with rosiglitazone, an effect certainly
central to the adipogenic effect of the NSAID. It is also possible that indomethacin affects
PPARγ2 through post-transcriptional mechanisms.
Celecoxib, a potent inhibitor of COX2 and prostaglandin production, had little effect on
MSC lineage allocation. Knockdown of COX2 also failed to replicate the strong adipogenic
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effect of indomethacin, suggesting that COX2 products were not involved. PGE2, the
principal product of COX2, has been considered to function as anabolic agent that both
promotes osteoblastogenesis and decreases adipogenesis [Zhang et al., 2002]. This view
should be modified in light of the fact that COX2−/− mice have no fat phenotype and a
minimal bone phenotype is found in males only [Robertson et al., 2006]. In vivo
administration of PGE2 has, further, not been consistently anabolic [Ueno et al., 1985;
Suponitzky and Weinreb, 1998] and in our experiments, PGE2 failed to prevent early
adipogenesis. Interestingly, Xie et al. [2009] recently demonstrated that COX2 and PGE2
contribute to angiogenesis in the setting of fracture healing, invoking a new level of
prostaglandin regulation of processes central to bone remodeling. Thus, while COX2 and
PGE2 may have roles in the pathologic setting of fracture healing, a clear role for prostanoid
signaling during MSC differentiation has not emerged [Zhang et al., 2002; Xie et al., 2009].
A growing body of literature supports non-cyclooxygenase mediated mechanisms for
NSAIDs [Tegeder et al., 2001]. These drugs can have differential effects on transcription
factors, MAP kinases, and cell cycle regulators [Tegeder et al., 2001]. Indomethacin
induction of gastric ulceration was originally ascribed to inhibition of COX1 and
prostaglandin production, however prostaglandin failed to reverse effects of indomethacin in
gastric cell culture [Langenbach et al., 1995; Kokoska et al., 1998]. Additionally, antitumor
effects of celecoxib in colorectal cancer cells appear to be mediated via COX-2 independent
mechanisms [Grosch et al., 2001]. Indomethacin’s COX-independent promotion of
adipogenesis can now be added to this list.
Although indomethacin has been shown to bind PPARγ2 [Lehmann et al., 1997], doses that
strongly induce adipogenesis failed to activate a PPRE-driven reporter construct. Our results
contrast with those of Lehmann et al. [1997]: it is possible that rising PPARγ2 levels
enhanced expression of the aP2 promoter used in those experiments. Our experiments
controlled for indomethacin’s strong induction of PPARγ2 by forced expression of both
PPARγ2 and RXRα in the target cells. An interaction between indomethacin and the ligand
binding domain (LBD) of PPARγ2 has also been suggested [Lehmann et al., 1997]; that
other NSAIDs at very high doses have been shown to interact with the PPARγ LBD yet
none induce adipogenesis suggests that induction of adipogenesis by indomethacin is not via
this association. Furthermore, the profound upregulation of PPARγ2 expression induced by
indomethacin indicates that crucial events take place upstream of PPARγ2.
C/EBPβ serves as transcription factor required early during adipogenesis [Park et al., 2004].
A C/EBPβ dominant-negative mutation that fails to enter the nucleus of 3T3-L1 cells
blocked mitotic clonal expansion of pre-adipocytes [Zhang et al., 2004]. The induction of C/
EBPβ due to indomethacin thus likely precedes the downstream expression of PPARγ2.
Indomethacin has been found to induce Nur77 [Kang et al., 2000], a member of the of the
steroidthyroid hormone nuclear receptor family. Given that Nur 77 has been linked to early
adipogenic conversion [Fumoto et al., 2007] it is possible that indomethacin via effects on
Nur77 DNA-binding might result in increased transcription of C/EBPβ. Interestingly, new
evidence has emerged linking C/EBPβ to endoplasmic reticulum (ER) stress [Matsuda et al.,
2010], and contributors to the ER stress response are directly dependent on C/EBPβ and
have been shown to be required for adipogenesis [Sha et al., 2009]. As indomethacin has
been shown to increase markers of ER stress like BiP (Grp78) and CHOP [Tsutsumi et al.,
2004], it is possible that indomethacin upregulation of C/EBPβ is interlinked with ER stress.
In summary, our results indicate that indomethacin strongly promotes adipogenesis through
a prostaglandin independent mechanism that increases both C/EBPβ and PPARγ2.
Understanding the effect of NSAIDs, and in particular indomethacin, on lineage allocation
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of MSC is important not only because NSAIDs are commonly used drugs, but also because
they shed light on mechanisms involved in early adipogenesis.
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Indomethacin is a potent stimulator of adipogenesis in MSCs. A: Phase-contrast 10×
Photomicrographs of C3H10T1/2 stem cells cultured in adipogenic media ± rosiglitazone
(10 µM), indomethacin (10 µM) or celecoxib (10 µM), day 3. B: Representative immunoblot
analysis of C3H10T1/2 cells at day 3 in the presence of vehicle, indomethacin (50 µM),
celecoxib (10 µM), or rosiglitazone (10 µM). Protein expression normalized to β-tubulin n =
2. C: Representative immunoblot of marrow-derived MSCs (mdMSC) at day 3 in the
presence of vehicle, indomethacin (50 µM), or celecoxib (10 µM) n = 3; ***P < 0.001.
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Indomethacin accelerates adipogenesis and degradation of b-catenin. A: RT-PCR analysis of
mRNA harvested from C3H10T1/2 stem cells cultured in triplicate in adipogenic media ±
indomethacin (50 µM) at indicated time points. COX2, PPARγ2, and adiponectin mRNA
adjusted to 18S and normalized to day zero controls. COX2 mRNA levels at each time point
compared to day zero controls. B: Immunoblot analysis of C3H10T1/2 stem cells cultured in
adipogenic media for indicated number of days ± indomethacin (50 µM) analyzed for
COX2, PPARγ, adiponectin (APN), aP2, total and active β-catenin. **P < 0.01, ***P <
0.001.
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Celecoxib, a selective COX2 inhibitor, fails to replicate Indomethacin’s adipogenic effect.
A: Representative immunoblots of C3H10T1/2 stem cells cultured in adipogenic media ±
indomethacin or celecoxib at indicated doses and time points analyzed for adiponectin
(APN), aP2, and PPARγ. B: C3HT101/2 stem cells were treated with arachidonic acid (25
µM), indomethacin and celecoxib at indicated doses (µM). Media PGE2 is reported; **P <
0.01.
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Indomethacin’s adipogenic effect is independent of COX2 and PGE2. A: RT-PCR of C3H
cells ± indomethacin (50 µM), ±PGE2 (5 µM) expressed as fold increase over control. B:
Western blot analysis of MSCs as in (A). C: MSCs in adipogenic media were transfected
with siRNA to COX2 or siSCR (control). RT-PCR for COX2, PPARγ, and adiponectin
(APN) was analyzed at 72 h. Bars represent means ± SEM, n = 2. D: Representative western
blot analysis of MSCs transfected with siCOX2 versus siSCR at 72 h, n = 3; ***P < 0.001.
Styner et al. Page 14














Indomethacin does not transactivate PPRE-luciferase construct. C3H10T1/2 cells were co-
transfected with Flag-PPARγ2 and RXRα or empty vector control as well as the PPRE-
LUC vector. β-galactosidase was used to control for transfection efficiency. A: Immunoblot
analysis for Flag-PPARγ2 and PPARγ2 24 h after transfection. B: Indomethacin (50 µM),
rosiglitazone (20 µM), 15d-PGJ2 (10 µM) or vehicle were added 24 h after transfection.
PPRE-LUC reporter assay was performed 48 h later, n = 3; **P < 0.01.
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Indomethacin induces C/EBPβ. A, left panel: C3H10T1/2 stem cells were cultured ±
indomethacin (50 µM) at indicated time points and analyzed in triplicate by RT-PCR for C/
EBPβ n = 3. A right panel, mdMSCs were cultured ± indomethacin (50 µM) at indicated
time points were analyzed by RT-PCR for C/EBPb n = 3. B: Protein analysis confirms dose
effect of indomethacin on C/EBPβ in C3H10T1/2 stem cells. C: C/EBPβ protein induced by
indomethacin (50 µM) at day 3, n = 2; **P < 0.01.
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